EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

Sarina A Piha-Paul iD, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D Kawedia, Siqing Fu, Shubham Pant, Timothy A Yap, Van K Morris und 4 weitere

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-023-04545-4 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Sarina A Piha-Paul und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, 1515 Holcombe B…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Puma Biotechnology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant or compensatory mechanisms. Herein, we sought to determine the feasibility and safety of neratinib and trametinib in patients with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation and KRAS mutation.

Methods

Patients with actionable somatic mutations or amplifications in ERBB genes or actionable KRAS mutations were enrolled to receive neratinib and trametinib in this phase I dose escalation trial. The primary endpoint was determination of the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary endpoints included pharmacokinetic analysis and preliminary anti-tumor efficacy.

Results

Twenty patients were enrolled with a median age of 50.5 years and a median of 3 lines of prior therapy. Grade 3 treatment-related toxicities included: diarrhea (25%), vomiting (10%), nausea (5%), fatigue (5%) and malaise (5%). The MTD was dose level (DL) minus 1 (neratinib 160 mg daily with trametinib 1 mg, 5 days on and 2 days off) given 2 DLTs of grade 3 diarrhea in DL1 (neratinib 160 mg daily with trametinib 1 mg daily). The treatment-related toxicities of DL1 included: diarrhea (100%), nausea (55.6%) and rash (55.6%). Pharmacokinetic data showed trametinib clearance was significantly reduced leading to high drug exposures of trametinib. Two patients achieved stable disease (SD) ≥ 4 months.

Conclusion

Neratinib and trametinib combination was toxic and had limited clinical efficacy. This may be due to suboptimal drug dosing given drug–drug interactions.

Trial registration

ID: NCT03065387.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)NeoplasmsHumansMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsGenes, erbBMutationErbB ReceptorsNauseaDiarrheaMitogen-Activated Protein Kinase KinasesErb-b2 Receptor Tyrosine KinasesPyridonesPyrimidinonesQuinolines

Stichwörter der Autor:innen

EGFRERBB familyKRASNeratinibTrametinib

Substanzen

Proto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsErbB ReceptorsMitogen-Activated Protein Kinase KinasesErb-b2 Receptor Tyrosine KinasestrametinibPyridonesPyrimidinonesneratinibQuinolines

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX, 77030, USA. spihapau@mdanderson.org.
  • Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX, 77030, USA.
  • Department of Thoracic, Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pharmacy Pharmacology Research, Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Sarina A Piha-Paul

Förderung

  • Puma Biotechnology

Zitieren

APA

Piha-Paul, S. A., Tseng, C., Tran, H. T., Gao, M., Karp, D. D., Subbiah, V., Tsimberidou, A. M., Kawedia, J. D., Fu, S., Pant, S., Yap, T. A., Morris, V. K., Kee, B. K., Blum Murphy, M., Lim, J., & Meric-Bernstam, F. (2023). A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04545-4

Vancouver

Piha-Paul SA, Tseng C, Tran HT, Gao M, Karp DD, Subbiah V, et al. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04545-4

BibTeX
@article{PihaPaul2023,
  author = {Piha-Paul, Sarina A and Tseng, Chieh and Tran, Hai T and Gao, Meng and Karp, Daniel D and Subbiah, Vivek and Tsimberidou, Apostolia Maria and Kawedia, Jitesh D and Fu, Siqing and Pant, Shubham and Yap, Timothy A and Morris, Van K and Kee, Bryan K and Blum Murphy, Mariela and Lim, JoAnn and Meric-Bernstam, Funda},
  title = {A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-023-04545-4}
}
Kostenlos starten →